New hope for eczema sufferers: dupilumab improves skin barrier in chinese patients
NCT ID NCT05624112
First seen Oct 01, 2025 · Last updated May 24, 2026 · Updated 35 times
Summary
This study looked at how dupilumab affects the skin barrier in 44 Chinese patients with moderate to severe atopic dermatitis (eczema). Over 16 weeks, researchers measured water loss from the skin to see if the treatment helped strengthen the barrier. The goal was to understand how well dupilumab works in this specific group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dermatology Hospital of Southern Medical University (Guangdong Provincial Dermatology Hospital)
Guangzhou, Guangdong, 510091, China
Conditions
Explore the condition pages connected to this study.